Recombinant Antibodies

Tinurilimab (anti-CEACAM6) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tinurilimab (anti-CEACAM6) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tisotumab (anti-F3) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab (anti-F3) can be used for the research of solid tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tisotumab (anti-F3) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab (anti-F3) can be used for the research of solid tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tisotumab (anti-F3) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab (anti-F3) can be used for the research of solid tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tisotumab (anti-F3) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab (anti-F3) can be used for the research of solid tumors.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Tralokinumab (anti-IL-13), a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab (anti-IL-13) can be used for the

Tralokinumab (anti-IL-13), a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab (anti-IL-13) can be used for the

Tralokinumab (anti-IL-13), a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab (anti-IL-13) can be used for the

Tralokinumab (anti-IL-13), a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab (anti-IL-13) can be used for the

Tregalizumab (anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab (anti-CD4) can be used in the research of autoimmune

TTX-030 (anti-ENTPD1) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP)